Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10239911

Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nuc

Atea Pharmaceuticals, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10238659

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagoni

Corcept Therapeutics Incorporated · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10238652

Compounds for treatment of cancer

Curegenix, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10238606

Pharmaceutical compositions for the treatment of Helicobacter pylori

RedHill Biopharma Ltd. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10238618

Compositions and methods for diagnosis and treatment of anemia

United States of America as represented by the Secretary of the Air Force · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10233222

Methods, compositions, diagnostics and assays for the treatment of Alzheimer's disease

The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10232044

Controlled release aural pressure modulator compositions and methods for the treatment of

The Regents of the University of California · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10231983

Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucoc

Corcept Therapeutics Incorporated · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10231932

Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseas

Vertex Pharmaceuticals Incorporated · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10227323

Glucosylceramide synthase inhibitors for the treatment of diseases

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10227312

Glucosylceramide synthase inhibitors for the treatment of diseases

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10226472

Methods for the treatment of breast cancer

Syndax Pharmaceuticals, Inc. · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10226420

Methods of eye treatment using therapeutic compositions containing dipyridamole

O.D. Ocular Discovery Ltd. · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10221226

LEDGF peptides and formulations thereof for treatment of degenerative disorders

The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10220046

Compositions and methods for disease treatment using nanoparticle delivered compounds

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10220029

Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treat

OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES” · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10215762

Method to optimize the treatment of patients with biological drugs

PROGENIKA BIOPHARMA, S.A. · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10214726

Compositions and methods for prevention or treatment of neoplastic disease in a mammalian

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10214529

Small molecules for the treatment of primary cancer and cancer metastasis

The Board of Regents of the University of Texas System · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10213478

Compositions and methods for the treatment of fungal infections

Arizona Board of Regents on Behalf of Northern Arizona University · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10213395

Toxic aldehyde related diseases and treatment

Aldeyra Therapeutics, Inc. · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10208059

Heterocyclic modulators of HIF activity for treatment of disease

The Board of Regents of the University of Texas System · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10206933

Non-hormonal steroid modulators of NF-kB for treatment of disease

ReveraGen BioPharma, Inc. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10206877

Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance

Vertex Pharmaceuticals Incorporated · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted